CY1109502T1 - Φαρμακοτεχνικη μορφη μιας θειενοπυριδινης ως αναστολεας της συσσωματωσης αιμοπεταλιου - Google Patents

Φαρμακοτεχνικη μορφη μιας θειενοπυριδινης ως αναστολεας της συσσωματωσης αιμοπεταλιου

Info

Publication number
CY1109502T1
CY1109502T1 CY20091101101T CY091101101T CY1109502T1 CY 1109502 T1 CY1109502 T1 CY 1109502T1 CY 20091101101 T CY20091101101 T CY 20091101101T CY 091101101 T CY091101101 T CY 091101101T CY 1109502 T1 CY1109502 T1 CY 1109502T1
Authority
CY
Cyprus
Prior art keywords
thienopyridine
inhibitor
blood collection
pharmaceutical form
prasugrel
Prior art date
Application number
CY20091101101T
Other languages
English (en)
Inventor
David Brian Dziennik
Tamara Beth Edelman
Peter Lloyd Oren
Robert Louis Ternik
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109502(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1109502T1 publication Critical patent/CY1109502T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Φαρμακοτεχνική μορφή μιας ένωσης του τύπου (Ι), πρασουγρέλης, που συσκευάζεται σε αεροστεγή και αδιαπέραστη στην υγρασία συσκευασία διαφανούς κυψέλης με αδρανές αέριο.
CY20091101101T 2005-06-10 2009-10-22 Φαρμακοτεχνικη μορφη μιας θειενοπυριδινης ως αναστολεας της συσσωματωσης αιμοπεταλιου CY1109502T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10
EP06772240A EP1896019B1 (en) 2005-06-10 2006-06-06 Formulation of a thienopyridine platelet aggregation inhibitor

Publications (1)

Publication Number Publication Date
CY1109502T1 true CY1109502T1 (el) 2014-08-13

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101101T CY1109502T1 (el) 2005-06-10 2009-10-22 Φαρμακοτεχνικη μορφη μιας θειενοπυριδινης ως αναστολεας της συσσωματωσης αιμοπεταλιου

Country Status (35)

Country Link
US (1) US20080176893A1 (el)
EP (1) EP1896019B1 (el)
JP (1) JP2008543755A (el)
KR (2) KR20100076050A (el)
CN (1) CN101193633B (el)
AR (1) AR054283A1 (el)
AT (1) ATE441413T1 (el)
AU (1) AU2006258102B2 (el)
BR (1) BRPI0611350B8 (el)
CA (1) CA2611668C (el)
CY (1) CY1109502T1 (el)
DE (1) DE602006008942D1 (el)
DK (1) DK1896019T3 (el)
DO (1) DOP2006000126A (el)
EA (1) EA011693B1 (el)
EC (1) ECSP077984A (el)
ES (1) ES2330373T3 (el)
HK (1) HK1116422A1 (el)
HR (1) HRP20090516T1 (el)
IL (1) IL187830A0 (el)
MA (1) MA29688B1 (el)
MX (1) MX2007015431A (el)
MY (1) MY151038A (el)
NO (1) NO20076317L (el)
NZ (1) NZ564003A (el)
PE (1) PE20070320A1 (el)
PL (1) PL1896019T3 (el)
PT (1) PT1896019E (el)
RS (1) RS51194B (el)
SI (1) SI1896019T1 (el)
TN (1) TNSN07466A1 (el)
TW (1) TWI318571B (el)
UA (1) UA91051C2 (el)
WO (1) WO2006135605A2 (el)
ZA (1) ZA200710697B (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072535A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
KR101503083B1 (ko) * 2006-12-07 2015-03-16 다이이찌 산쿄 가부시키가이샤 고형 제제의 제조 방법
KR101647842B1 (ko) * 2006-12-07 2016-08-11 다이이찌 산쿄 가부시키가이샤 저장 안정성이 개선된 의약 조성물
EP2100609A4 (en) * 2006-12-07 2010-01-06 Daiichi Sankyo Co Ltd MEDICAL PREPARATION IN SOLID FORM CONTAINING MANNITOL OR LACTOSE
AU2007333302A1 (en) * 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
KR101665705B1 (ko) * 2006-12-07 2016-10-12 다이이찌 산쿄 가부시키가이샤 안정성이 개선된 필름 코팅 제제
CN102424686A (zh) * 2007-03-02 2012-04-25 第一三共株式会社 用于制备高纯度普拉格雷盐酸盐的方法
KR20160033792A (ko) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
WO2009098142A1 (en) * 2008-02-06 2009-08-13 Helm Ag Prasugrel salts with improved properties
EP2107061A1 (en) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically enriched clopidogrel
DE602008002820D1 (de) * 2008-04-25 2010-11-11 Sandoz Ag Hydrogensulfat von 2-Acetoxy-5-(a-cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothienoÄ3,2-cÜpyridin und dessen Zubereitung
EA024980B1 (ru) * 2009-02-17 2016-11-30 КРКА, д.д., НОВО МЕСТО Лекарственные формы, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
US8236782B2 (en) 2009-05-13 2012-08-07 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014060554A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Prasugrel formulations
WO2014060560A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
PT1728794E (pt) * 2000-07-06 2008-07-15 Ube Industries Sal de adição maleato de derivados de hidropiridina
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
EP1243524A3 (en) * 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
DE602004010817T2 (de) * 2003-08-05 2008-12-11 Zentiva, A.S. Verfahren zur stabilisierung von atorvastatin

Also Published As

Publication number Publication date
TNSN07466A1 (en) 2009-03-17
ZA200710697B (en) 2009-08-26
TW200718420A (en) 2007-05-16
MA29688B1 (fr) 2008-08-01
ECSP077984A (es) 2008-01-23
JP2008543755A (ja) 2008-12-04
EA200702670A1 (ru) 2008-04-28
KR20080008413A (ko) 2008-01-23
EP1896019B1 (en) 2009-09-02
AU2006258102B2 (en) 2011-09-15
BRPI0611350B1 (pt) 2020-09-15
IL187830A0 (en) 2008-04-13
ATE441413T1 (de) 2009-09-15
CA2611668A1 (en) 2006-12-21
EA011693B1 (ru) 2009-04-28
RS51194B (sr) 2010-10-31
UA91051C2 (ru) 2010-06-25
DE602006008942D1 (en) 2009-10-15
ES2330373T3 (es) 2009-12-09
MY151038A (en) 2014-03-31
CN101193633B (zh) 2011-12-14
PT1896019E (pt) 2009-11-19
PE20070320A1 (es) 2007-05-12
KR20100076050A (ko) 2010-07-05
DOP2006000126A (es) 2006-12-15
SI1896019T1 (sl) 2010-01-29
WO2006135605A3 (en) 2007-04-12
MX2007015431A (es) 2008-02-21
DK1896019T3 (da) 2009-10-26
AR054283A1 (es) 2007-06-13
CA2611668C (en) 2013-10-15
WO2006135605A2 (en) 2006-12-21
NO20076317L (no) 2008-02-29
BRPI0611350B8 (pt) 2021-05-25
HRP20090516T1 (en) 2009-10-31
EP1896019A2 (en) 2008-03-12
CN101193633A (zh) 2008-06-04
US20080176893A1 (en) 2008-07-24
BRPI0611350A2 (pt) 2010-12-07
TWI318571B (en) 2009-12-21
PL1896019T3 (pl) 2010-01-29
AU2006258102A1 (en) 2006-12-21
HK1116422A1 (en) 2008-12-24
NZ564003A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
CY1109502T1 (el) Φαρμακοτεχνικη μορφη μιας θειενοπυριδινης ως αναστολεας της συσσωματωσης αιμοπεταλιου
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
CY1115838T1 (el) Μεθοδος για τη σταθεροποιηση φαρμακοτεχνικων μορφων που περιεχουν μικροοργανισμους
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
CY1122084T1 (el) Συνθεσεις που περιλαμβανουν αμλοδιπινη και μπισοπρολολη
UY29844A1 (es) Formulación en aerosol para la inhalación de beta-agonistas
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
UY30789A1 (es) Derivados de adenina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
ECSP077335A (es) Inhibidores de la interaccion entre mdm2 y p53
ECSP088258A (es) Inhibidores de serina proteasas
CY1109369T1 (el) Υποκατεστημενες πυρρολοπυριδινες, οι ενωσεις που τις περιεχουν, η διαδικασια παρασκευης τους και η χρηση τους
CY1110097T1 (el) Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων
SV2009003348A (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen
UY31349A1 (es) Inhibidores de la interaccion entre mdm2 y p53
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
CY1108711T1 (el) Συνθεσεις βενζοθειαζολιου και η χρηση αυτων
EA200801137A1 (ru) Соединения для ингибирования апоптоза
EA200600761A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их
CY1114113T1 (el) Συνδυασμος ενος αναστολεα του κολπικου ρευματος if και ενος βητα-αναστολεα
DK1919867T3 (da) Lisofyllinanaloger og farmaceutiske anvendelser heraf
DK1530967T3 (da) Blisterpakning og dertil hörende fast dosisform
ATE433975T1 (de) Als inos-inhibitoren geeignete imidazopyridinderivate
NI200900114A (es) Nuevos derivados de azabiciclicos su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY32702A (es) Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.